182 related articles for article (PubMed ID: 23033260)
21. A double-blind, randomized study comparing the antihypertensive effect of eplerenone and spironolactone in patients with hypertension and evidence of primary aldosteronism.
Parthasarathy HK; Ménard J; White WB; Young WF; Williams GH; Williams B; Ruilope LM; McInnes GT; Connell JM; MacDonald TM
J Hypertens; 2011 May; 29(5):980-90. PubMed ID: 21451421
[TBL] [Abstract][Full Text] [Related]
22. Risk factors associated with a low glomerular filtration rate in primary aldosteronism.
Reincke M; Rump LC; Quinkler M; Hahner S; Diederich S; Lorenz R; Seufert J; Schirpenbach C; Beuschlein F; Bidlingmaier M; Meisinger C; Holle R; Endres S;
J Clin Endocrinol Metab; 2009 Mar; 94(3):869-75. PubMed ID: 19116235
[TBL] [Abstract][Full Text] [Related]
23. Alterations of calcium metabolism and of parathyroid function in primary aldosteronism, and their reversal by spironolactone or by surgical removal of aldosterone-producing adenomas.
Rossi E; Sani C; Perazzoli F; Casoli MC; Negro A; Dotti C
Am J Hypertens; 1995 Sep; 8(9):884-93. PubMed ID: 8541003
[TBL] [Abstract][Full Text] [Related]
24. The effect of statins on urinary albumin excretion and glomerular filtration rate: results from both a randomized clinical trial and an observational cohort study.
Atthobari J; Brantsma AH; Gansevoort RT; Visser ST; Asselbergs FW; van Gilst WH; de Jong PE; de Jong-van den Berg LT;
Nephrol Dial Transplant; 2006 Nov; 21(11):3106-14. PubMed ID: 16720593
[TBL] [Abstract][Full Text] [Related]
25. Mineralocorticoid receptor antagonists and renal involvement in primary aldosteronism: opening of a new era.
Catena C; Colussi G; Sechi LA
Eur J Endocrinol; 2013 Jan; 168(1):C1-5. PubMed ID: 23082005
[TBL] [Abstract][Full Text] [Related]
26. Sleep quality in patients with primary aldosteronism.
Hanusch FM; Fischer E; Lang K; Diederich S; Endres S; Allolio B; Beuschlein F; Reincke M; Quinkler M
Hormones (Athens); 2014; 13(1):57-64. PubMed ID: 24722127
[TBL] [Abstract][Full Text] [Related]
27. Ventricular repolarization before and after treatment in patients with secondary hypertension due to renal-artery stenosis and primary aldosteronism.
Maule S; Bertello C; Rabbia F; Milan A; Mulatero P; Milazzo V; Papotti G; Veglio F
Hypertens Res; 2011 Oct; 34(10):1078-81. PubMed ID: 21677661
[TBL] [Abstract][Full Text] [Related]
28. Rationale and design of the Eplerenone combination Versus conventional Agents to Lower blood pressure on Urinary Antialbuminuric Treatment Effect (EVALUATE) trial: a double-blinded randomized placebo-controlled trial to evaluate the antialbuminuric effects of an aldosterone blocker in hypertensive patients with albuminuria.
Ando K; Ohtsu H; Arakawa Y; Kubota K; Yamaguchi T; Nagase M; Yamada A; Fujita T;
Hypertens Res; 2010 Jun; 33(6):616-21. PubMed ID: 20379190
[TBL] [Abstract][Full Text] [Related]
29. Effects of intensified blood-pressure reduction on renal function and albumin excretion in primary hypertension. Addition of felodipine or ramipril to long-term treatment with beta-blockade.
Siewert-Delle A; Ljungman S; Hartford M; Wikstrand J
Am J Hypertens; 1995 Feb; 8(2):113-23. PubMed ID: 7755939
[TBL] [Abstract][Full Text] [Related]
30. SFE/SFHTA/AFCE consensus on primary aldosteronism, part 7: Medical treatment of primary aldosteronism.
Pechère-Bertschi A; Herpin D; Lefebvre H
Ann Endocrinol (Paris); 2016 Jul; 77(3):226-34. PubMed ID: 27315759
[TBL] [Abstract][Full Text] [Related]
31. Spironolactone in type 2 diabetic nephropathy: Effects on proteinuria, blood pressure and renal function.
van den Meiracker AH; Baggen RG; Pauli S; Lindemans A; Vulto AG; Poldermans D; Boomsma F
J Hypertens; 2006 Nov; 24(11):2285-92. PubMed ID: 17053552
[TBL] [Abstract][Full Text] [Related]
32. Change in kidney function after unilateral adrenalectomy in patients with primary aldosteronism: identification of risk factors for decreased kidney function.
Kim IY; Park IS; Kim MJ; Han M; Rhee H; Seong EY; Lee DW; Lee SB; Kwak IS; Song SH; Chung HC
Int Urol Nephrol; 2018 Oct; 50(10):1887-1895. PubMed ID: 29779118
[TBL] [Abstract][Full Text] [Related]
33. Effects of Treating Primary Aldosteronism on Renal Function.
Kramers BJ; Kramers C; Lenders JW; Deinum J
J Clin Hypertens (Greenwich); 2017 Mar; 19(3):290-295. PubMed ID: 27659389
[TBL] [Abstract][Full Text] [Related]
34. Kidney impairment in primary aldosteronism.
Wu VC; Yang SY; Lin JW; Cheng BW; Kuo CC; Tsai CT; Chu TS; Huang KH; Wang SM; Lin YH; Chiang CK; Chang HW; Lin CY; Lin LY; Chiu JS; Hu FC; Chueh SC; Ho YL; Liu KL; Lin SL; Yen RF; Wu KD;
Clin Chim Acta; 2011 Jul; 412(15-16):1319-25. PubMed ID: 21345337
[TBL] [Abstract][Full Text] [Related]
35. Long-term cardiac effects of adrenalectomy or mineralocorticoid antagonists in patients with primary aldosteronism.
Catena C; Colussi G; Lapenna R; Nadalini E; Chiuch A; Gianfagna P; Sechi LA
Hypertension; 2007 Nov; 50(5):911-8. PubMed ID: 17893375
[TBL] [Abstract][Full Text] [Related]
36. Effects of the selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension.
White WB; Duprez D; St Hillaire R; Krause S; Roniker B; Kuse-Hamilton J; Weber MA
Hypertension; 2003 May; 41(5):1021-6. PubMed ID: 12682082
[TBL] [Abstract][Full Text] [Related]
37. Preoperative masked renal damage in Japanese patients with primary aldosteronism: identification of predictors for chronic kidney disease manifested after adrenalectomy.
Utsumi T; Kawamura K; Imamoto T; Nagano H; Tanaka T; Kamiya N; Nihei N; Naya Y; Suzuki H; Ichikawa T
Int J Urol; 2013 Jul; 20(7):685-91. PubMed ID: 23190329
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and safety of mineralocorticoid receptors in mild to moderate arterial hypertension.
Pelliccia F; Rosano G; Patti G; Volterrani M; Greco C; Gaudio C
Int J Cardiol; 2015 Dec; 200():8-11. PubMed ID: 25466561
[TBL] [Abstract][Full Text] [Related]
39. Renal Outcomes in Medically and Surgically Treated Primary Aldosteronism.
Hundemer GL; Curhan GC; Yozamp N; Wang M; Vaidya A
Hypertension; 2018 Sep; 72(3):658-666. PubMed ID: 29987110
[TBL] [Abstract][Full Text] [Related]
40. Randomized Controlled Trial of Mineralocorticoid Receptor Blockade in Children with Chronic Kidney Allograft Nephropathy.
Medeiros M; Velásquez-Jones L; Hernández AM; Ramón-García G; Valverde S; Fuentes Y; Vargas A; Patiño M; Pérez-Villalva R; Ortega-Trejo JA; Barrera-Chimal J; Bobadilla NA
Clin J Am Soc Nephrol; 2017 Aug; 12(8):1291-1300. PubMed ID: 28536123
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
